New York, NY, United States of America

Nii O Koney



Average Co-Inventor Count = 9.2

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Somerville, MA (US) (2010)
  • Brighton, MA (US) (2010 - 2011)
  • New York, NY (US) (2012 - 2013)

Company Filing History:


Years Active: 2010-2013

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Nii O Koney: Innovator in Cancer Treatment

Introduction

Nii O Koney is a prominent inventor based in New York, NY, known for his significant contributions to the field of cancer treatment. With a total of eight patents to his name, Koney has focused on developing compounds that inhibit the interaction of BCL proteins, which play a crucial role in regulating cell growth and survival.

Latest Patents

Koney's latest patents include innovative compounds and methods aimed at inhibiting the interaction of BCL proteins with their binding partners. One of his notable inventions involves isoxazolidine-containing compounds that bind to BCL proteins and inhibit their function. These compounds have potential applications in treating disorders associated with hyperproliferation, such as cancer. Another aspect of his work relates to heterocyclic compounds that also target BCL proteins, providing methods for treating and modulating similar disorders.

Career Highlights

Throughout his career, Nii O Koney has worked with leading companies in the pharmaceutical industry, including Infinity Pharmaceuticals, Inc. and Infinity Discovery, Inc. His work has been instrumental in advancing research and development in cancer therapies.

Collaborations

Koney has collaborated with notable professionals in his field, including Alfredo C Castro and Edward Holson. These partnerships have contributed to the success of his innovative projects and patents.

Conclusion

Nii O Koney's work in developing compounds for cancer treatment showcases his dedication to innovation in the medical field. His contributions have the potential to make a significant impact on the treatment of hyperproliferative disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…